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ABSTRACT: Bacteria depend on a well-regulated iron homeostasis to survive
adverse environments. A key component of the iron homeostasis machinery is
the compartmentalization of Fe3+ in bacterioferritin and its subsequent
mobilization as Fe2+ to satisfy metabolic requirements. In Pseudomonas
aeruginosa Fe3+ is compartmentalized in bacterioferritin (BfrB), and its
mobilization to the cytosol requires binding of a ferredoxin (Bfd) to reduce
the stored Fe3+ and release the soluble Fe2+. Blocking the BfrB-Bfd complex in
P. aeruginosa by deletion of the bfd gene triggers an irreversible accumulation
of Fe3+ in BfrB, concomitant cytosolic iron deﬁciency and signiﬁcant
impairment of bioﬁlm development. Herein we report that small molecules
developed to bind BfrB at the Bfd binding site block the BfrB-Bfd complex,
inhibit the mobilization of iron from BfrB in P. aeruginosa cells, elicit a
bacteriostatic eﬀect on planktonic cells, and are bactericidal to cells embedded
in mature bioﬁlms.
KEYWORDS: bioﬁlm, Pseudomonas aeruginosa, bacterioferritin, iron homeostasis, iron metabolism
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from nonadhered, free living (planktonic) cells.15 Susceptibility
tests have shown that the minimal inhibitory concentration
(MIC) and minimal bactericidal concentration (MBC) of
antibiotics that are required to challenge bacteria in mature
bioﬁlms can be 10- to 100-fold higher than those required for
planktonic bacteria.16−18 This intrinsic tolerance to antibiotics,
which is thought to be an important reason for the persistence
of bioﬁlm infections,6,10 generates an urgent need to discover
novel antibiotics and to validate new targets for combatting the
threat posed by multidrug resistant organisms and overcoming
the limitations of conventional antibiotics to treat chronic
(bioﬁlm) infections.19−21
Iron is an essential element in biology, and a required
cofactor for many enzymes that participate in important
physiological processes, such as respiration, DNA synthesis,
and amino acid synthesis.22 Iron homeostasis in bacteria oﬀers
a signiﬁcant vulnerability because invading pathogens must
obtain essential iron from the host, but host-defenses maintain
the concentration of free iron at a vanishingly low level
(∼10−18 M).22 Pathogens have evolved mechanisms to “steal”

ntimicrobial resistant bacteria are a major threat to public
health. The World Health Organization (WHO) has
released a priority list of pathogens for which antibiotics are
urgently needed.1 Carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobactereceae are at the top
of the WHO priority list because of their resistance to multiple
drug classes and associated mortality. P. aeruginosa, one of the
leading Gram-negative pathogens associated with nosocomial
infections has a propensity to form bioﬁlms, which are
populations of bacteria living in organized structures
embedded in a self-produced matrix of DNA, proteins, and
polysaccharides.2−4 Although the preference of bacteria for a
bioﬁlm lifestyle was reported almost 80 years ago, the
ubiquitous involvement of bioﬁlms in chronic infection has
been recognized more recently.5,6 Bioﬁlm-related diseases are
typically persistent infections that develop relatively slowly, are
rarely resolved by the immune system and respond poorly or
transiently to antibiotics.7 Some examples are chronic wound
infection, chronic otitis media, osteomyelitis, recurrent urinary
tract infection, endocarditis, and cystic ﬁbrosis-associated
infections which can accelerate lung function decay in cystic
ﬁbrosis patients.8,9 Bioﬁlms can also colonize indwelling
catheters, stents, orthopedic implants, endotracheal tubes and
urinary catheters,10−12 and are ubiquitous in burn wounds and
in chronic nonhealing wounds, including diabetic foot ulcers,
pressure ulcers and venous leg ulcers.13,14 Bacteria in bioﬁlms
are thought to be phenotypically and physiologically diﬀerent
© 2020 American Chemical Society
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encouraged us to conduct a fragment-based structure-guided
campaign to discover inhibitors of the BfrB-Bfd complex.
These eﬀorts allowed us to identify derivatives of 4aminoisoindoline-1,3-dione which bind BfrB selectively at the
Bfd binding site,25 block the BfrB-Bfd complex in the
P. aeruginosa cytosol, and inhibit the mobilization of
bacterioferritin-stored iron.25 Challenging planktonic cultures
of P. aeruginosa with the 4-aminoisoindoline-1,3-dione
analogues elicited a dose-dependent growth inhibition
phenotype, thus providing proof of concept for the usefulness
of small molecules designed to inhibit the BfrB-Bfd complex as
probes to dysregulate iron homeostasis and weaken bacterial
cells.25 Herein we report on improvements made to the 4aminoisoindoline-1,3-dione derivatives which increase the
binding aﬃnity for BfrB and the bacteriostatic activity against
planktonic P. aeruginosa cells. Surprisingly, the 4-aminoisoindoline-1,3-dione derivatives are bactericidal to P. aeruginosa cells
embedded in mature bioﬁlms. The killing eﬀect of the BfrB-Bfd
complex inhibitors on bioﬁlm cells, which are normally
recalcitrant to several classes of commercial antibiotics, has
uncovered a rare weakness that may be exploited to control
bioﬁlms.

iron from their host, but these depend strongly on wellregulated iron homeostasis.23,24 Consequently, we have
proposed iron storage proteins as a new and speciﬁc target
for dysregulating bacterial iron homeostasis.23,25,26 Our work
has showed that although two ferritin-like molecules coexist in
P. aeruginosa, bacterioferritin B (BfrB) is the main iron storage
protein.23,27 Bacterioferritin, which only exists in bacteria, is a
spherical protein that can store up to ∼3000 Fe3+ ions in its
interior cavity (∼80 Å diameter). Bacterioferritin is unique in
that it binds 12 heme groups buried under the external protein
surface, which allows the heme propionates to protrude into
the interior cavity (Figure 1A).28,29 We demonstrated that

■

RESULTS AND DISCUSSION
Synthesis of 4-Aminoisoindoline-1,3-dione Derivatives. Solving the X-ray structure of the BfrB-Bfd complex30
and identifying the hot-spot residues participating at the
protein−protein interface33 provided a unique molecular
platform to study the mechanisms that enable mobilization
of bacterioferritin-stored iron.28 The structural information
also enabled a fragment based structure-guided strategy to
discover inhibitors of the BfrB-Bfd complex. Fragment
screening followed by eﬀorts to cocrystallize the fragment
hits with BfrB produced the X-ray crystal structure of BfrB in
complex with 4-aminoisoindoline-1,3-dione (8) binding at the
Bfd-binding site.25 The cocrystal structure informed a strategy
for fragment growth that produced a series of 4-(benzylamino)- and 4-((3-phenylpropyl)amino)isoindoline-1,3-dione analogues represented by 11 and 16 (Table 1), which are
derivatives of 8 with −(CH2)− and −(CH2)3− linkers,
respectively.25,38 These analogues were shown to selectively
bind BfrB at the Bfd binding site and to elicit a growth defect
in P. aeruginosa planktonic cell cultures.25 To increase the
binding aﬃnity of 11 and 16 for BfrB we looked for
information in the available structural data. For example, the
crystal structures of 11 and 16 bound to BfrB show clear
electron density deﬁning the aminoisoindoline-1,3-dione
(phthalimide) moieties. The hydroxy-substituted phenyl
rings, however, are less well-deﬁned by electron density,
suggesting that conformational disorder of the phenyl ring in
the cleft formed by L68 and E81 may inﬂuence the stability of
the complex.25 In an attempt to lower disorder of the phenyl
ring, we prepared a set of 4-aminoisoindoline-1,3-dione
derivatives bearing a relatively bulky halogen atom in the
phenyl ring (Table 1). A schematic summary of the
representative syntheses for compounds with −(CH2)− or
−(CH2)3− linkers is shown in Figure 2. For example,
compound KM-5-25 was prepared from 5-chlorosalicylaldehyde by reductive amination with 8 in N,N-dimethylformamide (DMF) solution using sodium triacetoxyborohydride as
the reducing agent. Compound KM-5-66 was prepared from 3chloro-5-hydroxybenzaldehyde; the phenol was protected with
tert-butyldimethylsilyl chloride (TBSCl) and the side chain

Figure 1. (A) BfrB from Pseudomonas aeruginosa (PDB ID 3is7) is a
spherical and hollow protein assembly which can store up to 3000
Fe3+ in the interior cavity. A heme molecule (cyan) binds between
two subunits, where it is buried under the exterior surface with the
heme propionates exposed to the interior cavity. (B) Structure of the
BfrB-Bfd complex (PDB ID 4E6K) where a Bfd molecule (blue)
binds at the interface of two BfrB subunits (green), above a heme
molecule (cyan). Electron transfer from the [2Fe-2S] cluster in Bfd to
the Fe3+ in the interior of BfrB is mediated by the heme. The resultant
Fe2+ exits the BfrB molecule for incorporation in bacterial metabolism.

mobilization of iron from BfrB requires speciﬁc interactions
with the bacterioferritin-associated ferredoxin (Bfd).30,31 The
structure of Bfd revealed a new class of [2Fe-2S] protein32 and
the crystal structure of the BfrB-Bfd complex showed that up
to 12 Bfd molecules can bind at identical sites on the BfrB
surface, at the interface of subunit dimers, above a heme
molecule (Figure 1B).30 The heme mediates electron transfer
between the [2Fe-2S] cluster of Bfd and the Fe3+ mineral
stored in the BfrB cavity, enabling mobilization of Fe2+ to the
cytosol.28,30 The Bfd binding sites on BfrB are equivalent and
independent, where Bfd binds with a Kd of 3 μM.33
Studies conducted with P. aeruginosa PAO1 and a mutant
where the bfd gene has been deleted (Δbfd) showed that in the
absence of Bfd iron is irreversibly accumulated in BfrB, thus
demonstrating that Bfd is required to mobilize iron stored in
bacterioferritin. These studies also showed that the irreversible
accumulation of iron in BfrB is accompanied by depletion of
free iron in the cytosol.23 Given that P. aeruginosa requires
suﬃcient environmental and intracellular iron reserves to
establish mature bioﬁlms,34−37 we reasoned that the iron
deﬁciency that ensues in the cytosol of the Δbfd cells might
adversely aﬀect bioﬁlm formation. Studies conducted to pursue
this idea showed that the Δbfd cells form poorly developed
bioﬁlms and that the bioﬁlm-embedded cells experience
cytosolic iron deﬁciency, even in iron-suﬃcient culture
media.26 These ﬁndings, which underscored the inhibition of
the BfrB-Bfd complex as a viable target to dysregulate iron
homeostasis and possibly develop novel antimicrobial tools,
124
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monium ﬂuoride (TBAF) in THF. Additional details are
presented in the Supporting Information.
4-Aminoisoindoline-1,3-dione Derivatives Elicit a
Bacteriostatic Eﬀect in Planktonic P. aeruginosa Cultures. The relative strength of the association between the
new analogues and BfrB was evaluated measuring the
dissociation constant Kd (Table 1, Figure S1). The results
show that installing a halogen atom in the phenyl ring
improves the binding aﬃnity of the derivatives relative to the
previously reported analogues 11 and 16. The Kd values of
halogen containing compounds with a −(CH2)− linker are on
average ∼2-fold lower when compared to the Kd exhibited by
11, and the Kd values of halogen-bearing analogues with a
−(CH2)3− linker are on average ∼5-fold lower than the Kd
measured for analogue 16. The relative eﬃcacy of the
analogues to inhibit P. aeruginosa planktonic growth was
evaluated by measuring the half maximal inhibitory concentration (IC50). Inspection of the data in Table 1 shows that all
of the halogenated compounds are more active than analogues
11 and 16; the activity of KM-5-29 and KM-5-54 could not be
evaluated because the relatively low aqueous solubility of these
compounds prevented measurement of their IC50 values.
Although the compounds synthesized so far do not include
all possible substitution isomers, some insights of the
governing structure activity relationships have begun to emerge
(Table 1): (i) Among the compounds with a −(CH2)− linker,
the data reveal that when the hydroxyl group is at position 2
relative to the linker (KM-5-29, JAG-5-7, KM-5-25, and KM5-30) a bulkier Cl atom at position 5 (KM-5-25) imparts ∼2fold higher binding aﬃnity for BfrB than a smaller F atom at
the same position (JAG-5-7). In line with the nearly 2-fold
lower Kd, the IC50 of KM-5-25 is ∼2-fold lower than that of
JAG-5-7. In comparison, a Cl atom at position 3 (KM-5-30)
imparts a Kd similar that of KM-5-25, but an IC50 ∼ 2.5-fold
larger, suggesting that KM-5-30 is less eﬃcient at penetrating
or accumulating in P. aeruginosa cells. Installing a Cl atom at
position 6 (KM-5-29) renders the compound poorly soluble in
aqueous solution. It is also interesting to compare the two
analogues with a hydroxyl group at position 3. The presence of
a Cl atom at position 5, KM-5-50, lowers the Kd by a factor of
2 relative to BN-XIV-53 and improves the activity vs
planktonic cells signiﬁcantly. (ii) Examining the compound
series with a −(CH2)3− linker shows that when the hydroxyl
group is at position 3, a Cl atom at position 5 (KM-5-66)
decreases the Kd ∼ 4-fold and the IC50 ∼ 3-fold relative to
compound 16. In comparison, the presence of a second
hydroxyl group at position 5 (KM-5-57) increases the Kd ∼
1.7-fold relative to 16 and renders the compound inactive.
Given that the Kd measured for KM-5-57 is similar or lower
than Kd values measured for other active compounds in Table
1, the immeasurable activity of KM-5-57 suggests that it
cannot penetrate or accumulate in P. aeruginosa cells. Finally,
comparison of compounds where the hydroxyl group is at
position 2 (KM-5-28, JAG-5-6, and KM-5-54) also shows that
a halogen at position 5 improves binding aﬃnity. A bulkier Cl
atom at position 5 increases the binding aﬃnity of KM-5-54 2fold relative to the compound with a F at the same position
(JAG-5-6). Comparing the IC50 values corresponding to KM5-28 and JAG-5-6 reveals that the ∼3-fold lower Kd caused by
installing a F atom at position 5 is accompanied by ∼2-fold
decrease in the IC50. Attempts to determine whether the lower
Kd obtained when a Cl atom at position 5 would bring an

Table 1. Structure, Binding Aﬃnity, and IC50 of 4Aminoisoindoline-1,3-dione Derivatives

*

Not determined because of low solubility (<30 μM) in PBS buﬀer.

Figure 2. Schematic summary of the synthetic process to prepare 4(benzylamino)isoindoline (i.e., KM-5-25) and 4-((3-phenylpropyl)amino)- (i.e., KM-5-66) derivatives of 4-aminoisoindoline-1,3-dione.

elongated by Horner−Wadsworth−Emmons reaction to the α,
β-unsaturated ester. Subsequent catalytic reduction of the side
chain double bond followed by diisobutylaluminum hydride
(DIBAL-H) reduction of the ester under carefully controlled
temperature conditions furnished the requisite 3-arylpropionaldehyde. This aldehyde was then linked by reductive
amination to 8 as above and deprotected with tetrabutylam125
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Figure 3. Binding of KM-5-66 to the Bfd binding site on BfrB. Subunits A and B of a BfrB subunit dimer are rendered as surface and colored in
gray and green, respectively. (A) Fo − Fc omit map contoured at 3σ (coral mesh) from KM-5-66 bound on BfrB. (B) Hydrogen bonding
interactions (dashed lines) between KM-5-66 and BfrB. (C) View along the 3-hydroxyl-5-chloro phenyl ring plane of KM-5-66 (coral) depicted as
a surface rendering along with residues surrounding the phenyl ring. (D) View depicting the 3-hydroxyl-5-chloro phenyl ring position relative to
residues M31 and W35; pertinent distances are indicated by solid lines. The Cl atom of KM-5-66 is depicted in green.

Figure 4. Binding of JAG-5-7 to the Bfd binding site on BfrB. (A,B) Fo − Fc omit map contoured at 3σ (coral mesh) from JAG-5-7 bound at the
Bfd binding site in one of the BfrB subunit dimers, and hydrogen bonding interactions (dashed lines). The 2-hydroxyl-5-ﬂuoro phenyl ring is
observed in only one conformation at this binding site. (C,D) View of a diﬀerent binding site where the 2-hydroxyl-5-ﬂuoro phenyl ring is observed
in two conformations; in one of the conformations the hydroxyl group is hydrogen bonded to the carbonyl oxygen of G80. The F atom of JAG-5-7
is depicted in green.

containing a −(CH2)− linker, and KM-5-66, the most active
of the analogues harboring a −(CH2)3− linker.
Structures of Representative 4-Aminoisoindoline1,3-dione Derivatives Bound to BfrB. To gain additional
evidence for the selectivity of the 4-aminoisoindoline-1,3-dione
derivatives for the Bfd binding site on BfrB, we carried out
ligand soaking experiments aimed at obtaining cocrystals of
compound bound to the bacterioferritin. These experiments
resulted in the X-ray crystal structures of KM-5-28, KM-5-66,
KM-5-50, and JAG-5-7 bound to BfrB; reﬁnement statistics
are summarized in Table S1. In all four structures the 4aminoisoindoline-1,3-dione (phthalimide) moiety binds at the
Bfd binding site with a nearly identical pose, forming hydrogen
bonding interactions to the O atom of P69 and the backbone
N atoms of L71 and N70 (Figures 3A,B, 4A,B, and S2). This
binding mode, which is nearly identical with that observed in
the previously reported structures of 11, 16, and several other
analogues,25 provides strong evidence for the selectivity of the
4-aminoisoindoline-1,3-dione derivatives for the Bfd site on
BfrB. The linkers and phenyl rings also bind BfrB at the Bfd
binding site, where they ﬁt in a cleft formed by the side chains
of L68 and E81. As will be discussed below, the details of
binding are particular to whether the compound harbors a
−(CH2)− or a −(CH2)3− linker and to the substitution
pattern on the ring.
The structure of KM-5-66 (Figure 3) shows the −(CH2)3−
linker wedged at the “ﬂoor” of the cleft formed by the side
chains of L68 and E81 on BfrB (Figure 3A,B), where it engages
in hydrophobic packing with the several residues forming the

additional decrease in the IC50 were stymied by the poor water
solubility of KM-5-54.
The structure−activity relationships (SAR) information
available thus far indicates that a halogen in the aryl ring of
the 4-aminoisoindoline-1,3-dione derivatives invariably improves binding aﬃnity for BfrB. In compounds with a
−(CH2)− linker, when the hydroxyl group is at position 2, a
Cl atom at position 5 imparts favorable properties, a Cl atom at
position 3 renders the compound poorly active vs P. aeruginosa,
despite relatively favorable Kd, and a Cl atom at position 6
imparts poor aqueous solubility. The preparation of compounds with a −(CH2)3− linker is more elaborate and
accessibility to suitable starting materials at reasonable prices is
also more limited. The information available thus far indicates
that although a Cl at position 5 is favorable whether the
hydroxyl group is at position 2 or 3, poor aqueous solubility
impairs the potential biological activity when the hydroxyl is at
position 2 (KM-5-54), despite having the most favorable Kd of
all compounds in Table 1. Attempts to increase aqueous
solubility by installing a hydroxyl group at position 5
succeeded in increasing solubility but rendered a compound
(KM-5-57) with lower aﬃnity for BfrB and inactive against
P. aeruginosa cells. As new compounds become available,
similar evaluation of binding aﬃnity and activity against
bacterial cells will continue to shed light on the structural
requirements that simultaneously enhance target aﬃnity in
vitro and activity against P. aeruginosa cells. For the purposes of
the studies described below, we chose to work with
compounds KM-5-25, the most active of the analogues
126
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cleft ﬂoor and with the hydrophobic portion of the L68 and
E81 side chains. The 3-hydroxyl-5-chloro phenyl ring, which is
nearly parallel with the cleft ﬂoor, enables the 3-hydroxyl group
to interact with the E81 carbonyl oxygen via H-bonding, and
the Cl atom to interact with the side chains of L63 and L68
(Figure 3A,B). The phenyl ring, at its closest point, is also 3.60
Å from the M31 CE atom, a favorable interaction that is also
probable to hinder rotation of the ring toward a perpendicular
position relative to the cleft ﬂoor (Figure 3C,D). It is also
interesting to note that the 3-hydroxyl-5-chloro phenyl ring is
positioned to form a pseudo edge-to-face interaction with the
indole ring of W35; the phenyl ring, at its closest position, is
3.77 Å from the indole ring CZ2 atom, the distance between the
centroids of the phenyl and the indole 6-member ring is 5.92
Å, and the angle between the planes of these rings is 67.4°,
suggesting a weak edge-to-face interaction.
Despite signiﬁcant eﬀort, we could not obtain good
diﬀraction data from BfrB crystals soaked in solutions
containing KM-5-25. However, we were able to obtain the
structure of the ﬂuorinated analogue JAG-5-7 (Figure 4).
Strong electron density consistent with JAG-5-7 was observed
in 8 of the 12 subunits. The shorter −(CH2)− linker places the
2-hydroxyl-5-ﬂuoro phenyl ring well within the cleft formed by
the side chains of L68 and E81, with the ring nearly
perpendicular to the cleft ﬂoor. The electron density from
the 2-hydroxyl-5-ﬂuoro phenyl ring is consistent with the ring
experiencing one orientation in certain subunits (Figure 4A,B)
and with the ring in two conformations in other subunits
(Figure 4C,D). In one of these orientations the hydroxyl group
forms a H-bond with the carbonyl oxygen of G80, whereas the
ﬂuorine atom packs against the side chain of L68. The
structure of KM-5-50 (Figure S2), also places the 3-hydroxyl5-chloro phenyl ring within the cleft formed by L68 and E81,
in a similar nearly perpendicular conformation relative to the
cleft ﬂoor, except that no H-bonding was observed for the 3hydroxyl group.
Taken together, the structures of the 4-aminoisonindoline1,3-dione derivatives reported here and those reported
previously25 provide important insights. The linkers and the
phenyl rings of all the compounds containing a −(CH2)3−
linker adopt nearly identical binding modes, with the phenyl
rings oriented parallel to the cleft ﬂoor (Figure S3) and
positioned to engage the 6 member ring of the indole in W35.
Superposing the structures of analogue 16 and KM-5-66
(Figure S4A) shows that the phenyl ring in 16 is notably
pitched relative to the phenyl ring in KM-5-66 (the angle
between the mean planes of both rings is 22.6°), and the 3hydroxyl group is not engaged in H-bonding interactions. In
comparison, the Cl atom at position 5 in KM-5-66 appears to
induce a nearly parallel orientation of the ring relative to the
cleft ﬂoor and a conformation that places the 3-hydroxyl within
H-bonding distance of the carbonyl oxygen of E81. Together,
the H-bonding engagement of the 3-hydroxyl group, the
packing of the Cl atom with the side chains of L63 and L68,
and the more extensive packing of the phenyl ring against the
cleft ﬂoor residues are probably responsible for the higher
aﬃnity of KM-5-66 for BfrB relative to 16. It is also interesting
to note that in the structures of all the compounds with a
shorter −(CH2)− linker the phenyl ring is nearly perpendicular to the cleft ﬂoor. This is illustrated by superposing the
structures of KM-5-66 and JAG-5-7 (Figure S4B), which
shows that the phenyl rings of both compounds adopt a nearly
perpendicular angle (74°) relative to one another. The

Article

structural information currently available suggests that the
shorter linker and the relatively less eﬃcient packing of the
phenyl ring against the hydrophobic portions of the L68 and
E81 side chains may contribute to the higher Kd values of these
compounds relative to those with a −(CH2)3− linker.
Planktonic P. aeruginosa Cells Treated with 4Aminoisoindoline-1,3-dione Derivatives Overproduce
Pyoverdine. Previous studies directed at evaluating the
repercussions of blocking the BfrB-Bfd complex in P. aeruginosa
cells relied on deleting the bfd gene (Δbfd). These
investigations showed that blockade of the BfrB-Bfd complex
in planktonic Δbfd cells causes an irreversible accumulation of
iron in BfrB and iron deﬁciency in the cytosol. The resultant
phenotype is hyperproduction of pyoverdine relative to the
wild type cells.23 Pyoverdine is a siderophore produced by
P. aeruginosa when the cells experience iron limitation.39 A
similar pyoverdine overproduction phenotype was observed
when wild type P. aeruginosa cells were treated with small
molecule inhibitors of the BfrB-Bfd complex (11 and 16).25
Therefore, to determine that compounds KM-5-25 and KM-566 inhibit iron mobilization from BfrB in the P. aeruginosa
cytosol, we investigated whether cells treated with these
compounds express the characteristic pyoverdine hyperproduction phenotype. To this end, planktonic cells were
cultured in the presence of KM-5-25 (70 μM) or KM-5-66
(50 μM) for 27 h in M63 media and the content of the
secreted pyoverdine in the cell-free spent media was analyzed
by measuring the ﬂuorescence intensity at 460 nm. Normalizing the intensity of pyoverdine ﬂuorescence to CFU/mL
shows that as expected, cells treated with KM-5-25 or KM-566 secrete ∼5-fold more pyoverdine than the untreated control
(Figure S5), an overproduction level similar to that observed
with the Δbfd mutant.23 These observations indicate that both
analogues bind BfrB in the P. aeruginosa cytosol, block the
BfrB-Bfd interaction and inhibit iron mobilization from BfrB,
resulting in cytosolic iron limitation that is manifested in a
pyoverdine hyperproduction phenotype. The cytosolic iron
limitation caused by treating planktonic cultures with KM-5-25
or KM-5-66 exerts a bacteriostatic eﬀect on the cells, as
indicated by the IC50 values in Table 1. In stark contrast, when
the same compounds are used to treat P. aeruginosa bioﬁlms, a
bactericidal eﬀect is observed. The results from these
experiments are discussed below.
4-Aminoisoindoline-1,3-dione Derivatives Kill P. aeruginosa Cells in Mature Bioﬁlms. A characteristic of
bioﬁlms is their high tolerance to antimicrobial agents.
Tolerance is a physiological condition which does not involve
mutation and enables bacteria to survive in the presence of
antibiotics.40−43 The persistent bioﬁlm phenotype is thought
to arise from several factors, including restricted penetration of
antibiotic molecules due to interactions with components of
the bioﬁlm matrix, slow cell metabolism in the bioﬁlm,
diﬀerential expression of speciﬁc genes, and the presence of
persister cells. In addition, bioﬁlms are composed of distinct
subpopulations that exhibit diﬀerent physiological activity;
cells in the bioﬁlm interior exhibit low metabolic activity,
distinct from the high metabolism of cells near the surface.40,44,45 The dissimilar metabolic activity is thought to
result from a concentration gradient of O2 and nutrients, which
are high at the bioﬁlm surface and low in the deeper layers of
the bioﬁlm.45,46 Commercial antibiotics that interfere with cell
replication (e.g., ciproﬂoxacin), or protein translation (e.g.,
tobramycin), preferentially kill the metabolically active bacteria
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Figure 5. Bioﬁlms cultured in ﬂow cells are tolerant to ciproﬂoxacin and tobramycin and susceptible to colistin. EYFP-expressing P. aeruginosa
PAO1 bioﬁlms were cultured for 3 days by ﬂowing AB media supplemented with 15 μM Fe and then treated for 24 h by ﬂowing the same media
containing antibiotic. Bioﬁlms were counterstained with Sytox Red and imaged with the aid of CLSM. Top-down views (x−y plane) are depicted
with side views (x−z plane) at the bottom. Viable cell mass is in yellow and dead cells and extracellular DNA in red. (A) Untreated (DMSO)
control, (B) 25× MIC ciproﬂoxacin (19 μM), (C) 25× MIC tobramycin (27 μM), (D) 25× MIC colistin (20 μM). (E) The % survival obtained
from viable biomass calculated with the aid of COMSTAT software. The scale of the bars represents 20 μm. p < 0.01 denoted by ** and p < 0.001
by *** relative to untreated.

Figure 6. P. aeruginosa cells embedded in mature bioﬁlms grown in ﬂow cells are susceptible to 4 aminoisoindoline-1,3-dione analogues. EYFPexpressing P. aeruginosa PAO1 bioﬁlms were cultured for 3 days by ﬂowing AB media supplemented with 15 μM Fe and then treated for 24 h with
4-aminoisoindoline-1,3-dione analogue. Bioﬁlms were counterstained with Sytox Red and imaged with the aid of CLSM. Top-down views (x−y
plane) are depicted with side views (x−z plane) at the bottom. Viable cell mass is in yellow and dead cells and extracellular DNA in red. (A)
Untreated (DMSO) control, (B) 0.6× IC50 KM-5-25 (40 μM), (C) 1.2× IC50 KM-5-25 (80 μM), (D) 0.36× IC50 KM-5-66 (15 μM), (E) 0.7×
IC50 KM-5-66 (30 μM), and (F) 1.2× IC50 KM-5-66 (50 μM). (G,H) The % survival obtained from viable biomass calculated with the aid of
COMSTAT software for cells treated with KM-5-25 and KM-5-66, respectively. The scale of the bars represents 20 μm. p < 0.01 denoted by **
and p < 0.001 by *** relative to untreated.

in the outer bioﬁlm layers, whereas cells in the bioﬁlm interior
survive,44,47−49 despite the ability of both antibiotics to diﬀuse
into the inner regions of the bioﬁlm.44,50 In contrast, some
antimicrobials that aﬀect membrane structure, such as colistin,
a “last-line” therapy to treat multidrug resistant infections,51−53
can kill cells in the deeper bioﬁlm layers.49
We tested the susceptibility of mature bioﬁlms to treatment
with analogues of 4-aminoisoindoline-1,3-dione using two
platforms, bioﬁlms cultured at the solid−liquid interface (ﬂow

cell bioﬁlms) and bioﬁlms cultured at the air−liquid interface
(pellicles). Bioﬁlms of P. aeruginosa cells expressing an
enhanced yellow ﬂuorescent protein (EYFP) were cultured
in ﬂow cells using AB minimal media supplemented with 15
μM Fe. 3-Day old bioﬁlms were treated for 24 h with
commercial antibiotics or with 4-aminoisoindoline-1,3-dione
analogues by ﬂowing AB media containing analogue or
commercial antibiotic, 0.025% hypromellose (HPMC), 1.5%
DMSO and 15 μM Fe. In most experiments the concentration
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Figure 7. Pellicle bioﬁlms are tolerant to ciproﬂoxacin and tobramycin, and susceptible to colistin. Pellicles of P. aeruginosa PAO1 expressing EYFP
were cultured in PI media supplemented with 20 μM Fe for 48 h, and then treated with antibiotics for 24 h. Pellicles were counterstained with
Sytox Red and imaged with the aid of CLSM. Images depict top-down views (squares) and side views (rectangles) where viable cells are shown in
yellow and dead cells and extracellular DNA in red. (A) Untreated (DMSO) control, (B) 25× MIC ciproﬂoxacin (19 μM), (C) 50× MIC
ciproﬂoxacin (38 μM), (D) 25× MIC tobramycin (27 μM), (E) 50× MIC tobramycin (54 μM), (F) 12.5× MIC colistin (10 μM), (G) 25× MIC
colistin (20 μM), (H) 50× MIC colistin (40 μM). (I) The % survival obtained from viable biomass calculated with the aid of COMSTAT software.
The scale of the bars represents 20 μm. p < 0.001 denoted by *** relative to untreated.

soluble during the 24 h treatment period, KM-5-25 was used at
concentrations 40 and 80 μM, equivalent to 0.6× and 1.2× the
IC50, and KM-5-66 was used at concentrations 15, 30, and 50
μM, equivalent to 0.36×, 0.7×, and 1.2× the IC50 (Table 1).
Representative CLSM images obtained after treating 3-day old
bioﬁlms with each of the analogues for 24 h show that both
compounds kill bioﬁlm cells in a concentration dependent
manner (Figure 6). Treatment with 50 μM KM-5-66 elicits a
similar level of killing as treatment with 80 μM KM-5-25. The
higher eﬃcacy exhibited by KM-5-66 agrees with its higher
binding aﬃnity for BfrB and lower IC50. Inspection of the
images obtained upon treatment with the higher concentrations of KM-5-25 or KM-5-66 clearly shows that the
inhibitors of the BfrB-Bfd complex kill the cells in the interior
of the bioﬁlm, leaving most of the viable cells located at the
bioﬁlm surface (Figure 6C,F). This pattern of killing is
reminiscent of previously reported observations showing that
treatment of bioﬁlms with Ga3+ preferentially kills cells in the
inner portion of the bioﬁlm.56 The same authors concluded
that cells in the bioﬁlm interior are more sensitive to Ga3+
because this population experiences a more pronounced iron
starvation. Therefore, we speculate that in bioﬁlms treated with
KM-5-25 or KM-5-66 the internal bioﬁlm population is more
susceptible to iron limitation caused by the nearly irreversible
accumulation of iron in BfrB. It is important to underscore that
although the mechanisms whereby iron starvation contribute
to cell death in the bioﬁlm interior are not yet understood, the
fact remains that perturbation of iron homeostasis, either by
systemic replacement of Fe3+ with Ga3+, or by selective
inhibition of the BfrB-Bfd complex, leads to bacterial cell
death.
To expand the observations made with ﬂow cell bioﬁlms
into a second bioﬁlm model we also studied the susceptibility
of bioﬁlms grown at the air−liquid interface (pellicles).57,58

of commercial antibiotics used was 25× or 50× MIC, and the
concentration of 4-aminoisoindoline-1,3-dione analogues was
between 0.36× and 1.2× the IC50. The treated bioﬁlms were
counterstained with the cell impermeable ﬂuorescent nucleic
acid dye Sytox Red and then imaged with the aid of confocal
laser scanning microscopy (CLSM). Figure 5A depicts a
representative image of the untreated control, illustrating
yellow-ﬂuorescent viable cells and red-stained dead cells and
extracellular DNA. Figures 5B and 5C show representative
images depicting 4-day old bioﬁlms tolerant to 24 h treatment
with ciproﬂoxacin or tobramycin, respectively, and Figure 5D
shows 4-day old bioﬁlms susceptible to 24 h treatment with
colistin. In agreement with previously reported observations,49,54 treatment with ciproﬂoxacin preferentially kills
cells at the bioﬁlm surface, leaving the interior of the bioﬁlm
almost unaﬀected (Figure 5B). In contrast, treatment with
colistin preferentially kills bacteria in the bioﬁlm interior,
leaving the bioﬁlm surface less aﬀected (Figure 5D).
COMSTAT software was used to attempt a quantitative
comparison of the bioﬁlm biomass by estimating the
biovolume, which is calculated as the overall volume/
substratum area (μm3/μm2).55 Comparing the bioﬁlm biomass
as the ratio of (untreated biomass)/(treated biomass)
expressed as % survival (Figure 5E) shows that ∼20% of
biomass remains viable (yellow ﬂuorescent) after treatment
with colistin at 25× MIC. In comparison, ∼60% and 70% of
biomass remains viable after treatment with 25× MIC
ciproﬂoxacin or tobramycin, respectively.
Having established that the bioﬁlms are susceptible to
colistin and signiﬁcantly tolerant to ciproﬂoxacin and
tobramycin, we treated similarly cultured 3-day old bioﬁlms
with KM-5-25 and KM-5-66 for 24 h. Compounds KM-5-25
and KM-5-66 are soluble in aqueous media to ∼110 and ∼80
μM, respectively. To ensure that the compounds remain
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Figure 8. 4-Aminoisoindoline-1,3-dione analogues kill P. aeruginosa cells embedded in pellicle bioﬁlms. Pellicles of P. aeruginosa PAO1 cells
expressing EYFP were cultured for 48 h in PI media supplemented with 20 μM Fe, and then treated with KM-5-25 or KM-5-66 for 24 h. Pellicles
were counterstained with Sytox Red and imaged with the aid of CLSM. Images depict top-down views (squares) and side views (rectangles) where
viable cells are shown in yellow and dead cells and extracellular DNA in red. (A) Untreated (DMSO) control, (B) 0.6× IC50 KM-5-25 (40 μM),
(C) 1.2× IC50 KM-5-25 (80 μM), (D) 0.36× IC50 KM-5-66 (15 μM), (E) 0.7× IC50 KM-5-66 (30 μM), and (F) 1.2× IC50 KM-5-66 (50 μM).
(G,H) The % survival obtained from viable biomass calculated with the aid of COMSTAT software for pellicles treated with KM-5-25 and KM-566, respectively. The scale of the bars represents 20 μm. p < 0.01 denoted by ** and p < 0.001 by *** relative to untreated.

Figure 9. Assessment of cell survival in pellicle bioﬁlms by dispersing and counting viable cells. EYFP-expressing P. aeruginosa PAO1 cells
embedded in two-day old pellicles treated for 24 h with antibiotic or 4-aminoisoindoline-1,3-dione derivatives were dispersed for enumeration of
viable culturable cells (CFU/mL). The % survival is expressed as the ratio CFU/mL(after treatment)/CFU/mL(pretreatment). Pellicles were treated for 24 h
with (A) tobramycin (27 or 54 μM) or colistin (20 or 40 μM), concentrations equivalent to 25× and 50× the corresponding MIC, (B) compound
KM-5-25 (40 and 80 μM) concentrations equivalent to 0.6× and 1.2× IC50, and (C) compound KM-5-66 (15, 30, and 50 μM), concentrations
equivalent to 0.36×, 0.7×, and 1.2× IC50. p < 0.001 denoted by *** relative to untreated.

concentrations 25× and 50× the MIC (Figure 7B−E), as is
evident by the yellow ﬂuorescence and near complete absence
of red-stained dead cells. In contrast, the pellicle bioﬁlms are
susceptible to colistin at concentrations above 10× MIC
(Figure 7F−H). Analysis of the images with COMSTAT,
which allowed a more quantitative comparison of cell survival
upon treatment with each of the antibiotics (Figure 7I),
conﬁrms tolerance to ciproﬂoxacin and tobramycin, but
sensitivity to colistin. Note that when the concentration of
colistin is 50× MIC the ﬂuorescence signal from viable cells
expressing EYFP is undetectable. When pellicle bioﬁlms are
challenged with compound KM-5-25 of KM-5-66 bacterial cell
death occurs in a concentration dependent manner (Figure 8).
These results agree with the idea that the 4-aminoisoindoline1,3-derivatives penetrate the bacterial cell and bind to their

Pellicle bioﬁlms (henceforth pellicles) are an attractive
alternative platform to study bioﬁlms because pellicles are
amenable to imaging by CLSM and to harvesting, which can
be desirable for additional bioﬁlm analysis.26 To determine the
susceptibility of pellicles to antibiotics or inhibitors of the BfrBBfd complex, we cultured 2-day old pellicles of EYFPexpressing P. aeruginosa cells in PI media supplemented with
20 μM Fe, as indicated in the Methods. The pellicles were
transferred onto glass coverslips by allowing the surface of the
coverslip to contact a pellicle. The coverslip-adhered pellicles
were subsequently exposed to treatment solution (AB media
supplemented with 15 μM Fe, 0.025% HPMC, 1.5% DMSO,
and antibiotic or analogue) for 24 h prior to staining with
Sytox Red and imaging with the aid of CLSM. The pellicle
bioﬁlms are tolerant to ciproﬂoxacin and tobramycin at
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Figure 10. 4-Aminoisoindoline-1,3-dione analogues are likely broadly active against P. aeruginosa strains. Two-day old pellicle bioﬁlms formed by
P. aeruginosa clinical isolates (PA_1081725 and PA_1076058) were challenged for 24 h with 4-aminoisoindoline-1,3-dione derivatives prior to
dispersing the cells for enumeration of viable culturable cells (CFU/mL). The % survival is expressed as the ratio of CFU/mL(after treatment)/CFU/
mL(pretreatment). Pellicles of (A) PA_1081725 or (B) PA_1076058 were treated with concentrations equivalent to 1.2× IC50 of KM-5-25 (80 μM), or
KM-5-66 (50 μM). (C) Antibiotic susceptibility of clinical isolates PA_1081725 and PA_1076058. p < 0.001 denoted by *** relative to untreated.

target in the P. aeruginosa cytosol. Inspection of the images and
analysis with COMSTAT (Figure 8G and H) shows that
compound KM-5-66 is more eﬃcacious than KM-5-25,
observations that are consistent with the lower Kd and IC50
values measured for KM-5-66. It is also important to note that
when compounds KM-5-25 and KM-5-66 are used at a
concentration of 80 μM and 50 μM, respectively (Figure
8G,H), which correspond approximately to 1.2× IC50, nearly
85% of the cells in the pellicle are killed. This eﬃcacy is similar
that observed with colistin when used at 20 μM, equivalent to
25× MIC (Figure 7I).
To assess the eﬃcacy of antibiotics and compounds with an
approach complementary to imaging with CLSM, we resorted
to dispersing bioﬁlm cells for subsequent enumeration of viable
cells (CFU/mL). To this end, we cultured pellicle bioﬁlms for
48 h in PI media containing 20 μM Fe and exposed them to
AB media containing 15 μM Fe and antibiotic or compound
for 24 h, as described above. The bioﬁlms were then harvested,
and the cells dispersed into sterile PBS by vortexing in the
presence of zirconia beads, prior to plating the cell suspensions
for subsequent enumeration of CFU/mL. The results from
these experiments are summarized in the plots of Figure 9
which show the % cell survival of pellicle-embedded cells after
challenges with antibiotic or compound, calculated from the
fraction CFU/mL(after treatment)/CFU/mL(pretreatment). When colistin is used to treat the pellicles at concentrations equivalent
to 25× and 50× MIC, the treated bioﬁlms exhibit ∼10% and
∼1% cell survival, respectively, relative to the pretreated
bioﬁlm (Figure 9A), corroborating the sensitivity of the
pellicles to colistin. In contrast, challenging the pellicles with
tobramycin (25× and 50× MIC) results in ∼70% survival
relative to the pretreated bioﬁlm, and nearly identical cell
survival relative to the untreated (DMSO control) pellicles
(Figure 9A). These observations, which are in good agreement
with those made with the aid of CLSM (Figure 7D−H)
corroborate that the pellicles are tolerant to tobramycin and
sensitive to colistin. Interestingly, attempts to enumerate cells
after challenging the pellicles with ciproﬂoxacin (25× or 50×
MIC) resulted in extremely low CFU/mL, ﬁndings which at
ﬁrst glance appear to be in conﬂict with the tolerance of the
bioﬁlms to ciproﬂoxacin observed in the CLSM images (Figure
7B,C). To reconcile these seemingly discrepant observations it
is important to consider that several stressors, including
ciproﬂoxacin, can induce a dormancy state in bacterial cells

known as the viable but not culturable (VBNC) state. A
characteristic of cells in the VBNC state is their inability to
develop into colonies on routine culture media, even though
the cells remain viable for long periods of time.59,60 Evidence
that bacterial cells can enter the VBNC has been obtained by
several distinct methods,60 one of which is the utilization of
bacteria engineered to constitutively express bioluminescent
proteins, and using the bioluminescence as a reporter of
metabolic activity. Studies conducted with P. aeruginosa
showed that following treatment with ciproﬂoxacin the
bioluminescence emitted by P. aeruginosa cells decreased
signiﬁcantly less than the viable cell counts (CFU/mL). The
perceived reduction in viable cell counts, which did not
correlate with the relatively high metabolic activity reported by
the small decrease in bioluminescence, indicated that
challenges with ciproﬂoxacin induce P. aeruginosa cells to
enter a VBNC state.61,62 Our observations suggest a similar
situation. Imaging the pellicles with CLSM following the 24 h
challenge with ciproﬂoxacin (Figure 7B,C) shows that most of
the cells are metabolically active (yellow ﬂuorescent), but
dispersion of the cells from the pellicles for enumeration of
CFU/mL shows a large reduction in culturable cells relative to
the untreated control. These observations strongly suggest that
treating the pellicles with ciproﬂoxacin induces the cells to
enter the VBNC state, thus rendering them tolerant to the
antibiotic. These ﬁndings, which highlight the complexities
associated with bioﬁlm embedded cells, also underscore the
importance of resorting to more than one platform to study the
eﬃcacy of antibioﬁlm agents.
Enumeration of CFU/mL was also carried out after
challenging pellicles with 4-aminoisoindoline-1,3-dione derivatives. Treating the pellicles with KM-5-25 at concentrations
equivalent to 0.6× and 1.2× IC50 results in ∼38% and ∼25%
survival relative to cells in the pretreated bioﬁlm (Figure 9B),
while treating with KM-5-66 at concentrations equivalent to
0.3×, 0.6×, or 1.2× IC50 results in approximately 57%, 21%,
and 15% survival relative to cells in the pellicles prior to
treatment (Figure 9C). These observations, which are in good
agreement with the eﬃcacy of the compounds evaluated by
COMSTAT analysis of the CLSM images, corroborate the
bactericidal activity of the compounds against P. aeruginosa
bioﬁlms, and provide additional evidence indicating that KM5-66 used at 50 μM (1.2× IC50) exhibits nearly the same
eﬃcacy as colistin used at 20 μM (25× MIC). We also used
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harvested cells were lysed, the lysate solution supernatant was
clariﬁed by centrifugation and then loaded onto native PAGE
gels for separation and subsequent staining with Ferene S,
which reacts with iron to develop a blue color. Since the viable
cell count dispersed from the pellicle bioﬁlms treated with
KM-5-25 or KM-5-66 was 42% and 37% of the cells in the
untreated pellicle (Figure 11A), the clariﬁed lysate super-

the strategy of dispersing and counting viable cells to compare
the relative eﬃcacy of analogues 11, 16, KM-5-25, and KM-566. To this end, pellicles formed by P. aeruginosa PAO1 cells
were treated (24 h) with each of the compounds at a
concentration of 50 μM. The results (Figure S6) show that the
compound activity against bioﬁlm (KM-5-66 > KM-5-25 > 16
> 11) track with the Kd and IC50 values (Table 1). Taken
together, these ﬁndings suggest that additional modiﬁcations
made to the structures of KM-5-25 or KM-5-66 which
improve the binding aﬃnity for BfrB have the potential to
produce molecules with similar or better eﬃcacy toward
bioﬁlms than colistin.
The results from experiments aimed at determining the
eﬃcacy of the 4-aminoisoindoline-1,3-dione derivatives presented so far have been conducted with the reference strain
P. aeruginosa PAO1. To investigate whether the compounds
are also active against other strains of P. aeruginosa, we cultured
pellicles of several clinical isolates from JMI Laboratories.
Isolates PA_1081725 and PA_1076058 were chosen for
additional testing because these strains exhibit relatively high
MIC values for several antibiotics (Figure 10C) and form
robust pellicles under the same culture conditions used to grow
pellicle bioﬁlms of P. aeruginosa PAO1. Challenging the
pellicles formed by PA_1081725 and PA_1076058 with
analogues KM-5-25 or KM-5-66 at concentrations equivalent
to 1.2× IC50 elicits approximately 80% reduction of viable cells
(Figure 10A,B), indicating that the activity of the 4aminoisoindoline-1,3-dione analogues is not unique to bioﬁlms
formed by the P. aeruginosa PAO1 strain. To gain a broader
understanding of the potential activity spectrum of the BfrBBfd inhibitors against P. aeruginosa strains, BLASTp63 was used
to ﬁnd homologues of BfrB and Bfd sequences in the >4400
P. aeruginosa genomes in the Pseudomonas Genome Database.64 The results reveal two important facts: (i) The bfrB
and bfd genes are adjacent to one another in all the
P. aeruginosa strains. (ii) There is an extremely high level of
conservation among the bfd and bf rB sequences. These
ﬁndings allow us to predict that the structures of the BfrB
and Bfd proteins, as well as the structures of the BfrB-Bfd
complexes, are highly conserved across P. aeruginosa strains,
thus suggesting that the 4-aminoisoindoline-1,3-dione derivatives can be expected to be broadly active against P. aeruginosa.
4-Aminoisoindoline-1,3-dione Derivatives Inhibit
Iron Mobilization from BfrB in P. aeruginosa Cells. The
results presented above demonstrate that the 4-aminoisoindoline-1,3-dione derivatives can kill cells in mature bioﬁlms. To
demonstrate that the bactericidal activity is likely a result of the
compounds engaging BfrB in the P. aeruginosa cytosol,
inhibiting the BfrB-Bfd complex and blocking iron mobilization from the bacterioferritin in the P. aeruginosa cytosol,
we carried out experiments aimed at visualizing the iron stored
in BfrB. These experiments capitalize on a strategy we reported
previously to demonstrate that the Δbfd mutant of P. aeruginosa
irreversibly accumulates iron in BfrB23 and to show that
analogue 16 inhibits iron mobilization from BfrB in planktonic
cells.25 To visualize BfrB-stored iron in bioﬁlm-embedded cells,
2-day old pellicles of P. aeruginosa PAO1 cells were treated for
24 h with analogue KM-5-25 (40 μM) or KM-5-66 (20 μM)
at a concentration predicted to kill approximately 50% of the
cells in the bioﬁlm. The treated pellicles were dispersed in
sterile PBS and the cell suspension was harvested by
centrifugation after a small aliquot had been sampled to
enumerate viable cells. To visualize iron stored in BfrB the

Figure 11. 4-Aminoisoindoline-1,3-dione analogues penetrate the
P. aeruginosa cell, bind BfrB, and inhibit mobilization of BfrB-stored
iron. (A) Treating pellicles with 0.6× IC50 KM-5-25 (40 μM) or 0.5×
IC50 KM-5-66 (20 μM) for 24 h reduces the number of viable cells to
<50%. (B) The iron stored in BfrB in the viable cells was visualized
with the aid of native PAGE gels stained with Ferene S, which stains
the iron in the interior cavity of BfrB. Recombinant BfrB (BfrBrec) was
used as a standard for the electrophoretic mobility of BfrB. The lane
corresponding to untreated control was loaded with 0.5× the volume
of the lanes loaded with lysates from treated pellicles to account for
the ∼2-fold larger number of viable cells in the untreated pellicles.
Lanes loaded with treated pellicle lysates show greater accumulation
of iron in BfrB relative to untreated cells. (C) Peak areas obtained
from densitometry analysis (ImageJ) of the bands in the native PAGE
gel of panel B indicate that there is ∼3-fold more iron stored in BfrB
in the treated cells relative to the untreated control. (D) Analysis of
total intracellular iron levels normalized to CFU/mL indicates ∼2.5fold higher iron levels in the pellicle-embedded cells treated with the
4-aminoisoindoline-1,3-dione analogues relative to untreated control.
Panel B shows results from a representative experiment from 3
biological replicates. Panels A, C, and D show the average of 3
biological replicates. p < 0.001 is denoted by *** relative to untreated.

natants from the untreated control were diluted approximately
2-fold prior to loading the native gels. Results obtained with a
representative gel are shown in Figure 11B, where it can be
observed that lanes loaded with lysate solutions from pellicles
treated with analogues KM-5-25 or KM-5-66 exhibit
signiﬁcantly higher Ferene S stain intensity than the lane
loaded with lysate solution from the untreated pellicle. To
enable quantitative comparison we measured the relative
intensities of the Ferene S-stained bands with the aid of
ImageJ. Comparing the resultant peak areas (Figure 11C)
shows that BfrB from the cells treated with KM-5-25 or KM-566 has ∼3-fold more iron relative to BfrB from cells in the
untreated pellicles. These ﬁndings provide strong evidence
indicating that compounds KM-5-25 and KM-5-66 bind BfrB
in the P. aeruginosa cytosol, inhibit the formation of the BfrBBfd complex required to mobilize iron from BfrB, and lead to
nearly irreversible iron accumulation in BfrB. Consistent with
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Figure 12. 4-Aminoisoindoline-1,3-dione derivatives enhance the eﬃcacy of colistin and tobramycin against P. aeruginosa bioﬁlms. Two-day old
pellicles of EYFP-expressing P. aeruginosa PAO1 were treated for 24 h with (A) colistin alone 25× MIC (20 μM), or 50× MIC (40 μM), KM-5-25
(80 μM) or KM-5-66 (50 μM) alone, equivalent to 1.2× IC50, or a combination of colistin and KM-5-25 or KM-5-66, and (B) tobramycin alone
25× MIC (27 μM) or 50× MIC (40 μM), KM-5-25 or KM-5-66 alone at a concentration equivalent to 1.2× IC50, or a combination of tobramycin
and KM-5-25 or KM-5-66. The % survival is expressed as the ratio CFU/mL(after treatment)/CFU/mL(pretreatment). p < 0.001 is denoted by *** in the
combination treatment relative to treatment with antibiotic alone.

survival when colistin is present at 50× MIC, which
correspond to nearly 1 log and 0.7 log reduction of viable
cells, respectively, compared to colistin alone. Encouraged by
these results we tested whether the 4-aminoisoindoline-1,3dione derivatives can also enhance the bactericidal activity of
tobramycin. The results are shown in Figure 12B: the
combination treatment with KM-5-25 results in ∼0.5%
survival when tobramycin is used at 25× MIC and ∼0.003%
survival when tobramycin is present at 50× MIC, which
correspond to approximately 2.5 log and 4.7 log reduction of
viable cells when compared to treatment with tobramycin
alone. The combination treatment with KM-5-66 results in 5%
survival when tobramycin is present at 25× MIC and 1%
survival when tobramycin is used at 50× MIC, which
correspond to approximately 1.5 log and 2 log reduction in
viable cells relative to treatment with tobramycin alone. It is
interesting to note that compound KM-5-66 is more eﬀective
at enhancing the eﬃcacy of colistin (Figure 12A), whereas
compound KM-5-25 is more eﬀective at enhancing the eﬃcacy
of tobramycin (Figure 12B). Additional studies are clearly
required to understand the underlying reasons.
The observations above, which indicate that the iron
limitation induced by inhibitors of the BfrB-Bfd complex can
increase the eﬃcacy of colistin and tobramycin against
bioﬁlms, are in good agreement with previous studies showing
that the Fe chelator HBDE is an eﬀective colistin adjunct
against P. aeruginosa,67 and the iron chelators deferoxamine
and deferasirox increase the eﬃcacy of tobramycin against
P. aeruginosa bioﬁlms.68 When taken together, the observations
made in the presence of HBDE, deferoxamine, deferasirox or
4-aminoisoindoline-1,3-dione derivatives, strengthen the idea
that inducing intracellular iron limitation is probably a viable
strategy to enhance the eﬃcacy of colistin or tobramycin
against bioﬁlms. Since colistin is often used as one of the very
few therapeutic options available to combat multidrug resistant
Gram-negative organisms such as Acinetobacter baumannii,
Pseudomonas aeruginosa, and Klebsiella pneumoniae,69,70 it is
encouraging that small molecule inhibitors of the BfrB-Bfd
complex are capable of increasing the eﬀectiveness of colistin

the nearly irreversible accumulation of iron in BfrB in cells
treated with KM-5-25 or KM-5-66, quantiﬁcation of the total
intracellular iron and normalizing the values to viable cell
counts demonstrates that P. aeruginosa cells dispersed from
pellicles treated with KM-5-25 or KM-5-66 harbor ∼2.5-fold
more intracellular iron than cells obtained from untreated
bioﬁlms (Figure 11D). Taken together, these observations
support the idea that 4-aminoisoindoline-1,3-derivatives
dysregulate iron homeostasis by inhibiting the BfrB-Bfd
complex, causing the accumulation of unusable iron in the
bacterial cell.
4-Aminoisoindoline-1,3-dione Derivatives Enhance
the Eﬃcacy of Colistin and Tobramycin against
Bioﬁlm-Embedded Cells. As demonstrated above and in
previous reports,65,66 mature bioﬁlms formed by P. aeruginosa
cells are susceptible to colistin and tolerant to tobramycin.
Since these bioﬁlms are also susceptible to the 4-aminoisoindoline-1,3-dione inhibitors of the BfrB-Bfd complex, we
asked whether these compounds would enhance the eﬃcacy of
colistin and tobramycin. To answer this question, we cultured
2-day old pellicle bioﬁlms of EYFP-expressing P. aeruginosa
PAO1 and treated them for 24 h with colistin alone,
compound alone (KM-5-25 or KM-5-66), and with a
combination of colistin and compound. In the combination
treatment experiments, the concentration of compound was
kept constant (1.2× IC50), while colistin was used at two
diﬀerent concentrations, equivalent to 25× and 50× MIC
(Figure 12A). Treatment with each of the compounds or with
colistin alone caused a reduction of viable cells similar to that
reported in Figure 9A. Challenging the pellicles with a
combination of colistin and compound, however, causes a
signiﬁcant additional reduction in the number of viable cells
(Figure 12A): the combination treatment with KM-5-66
results in ∼0.3% survival when colistin is present at 25× MIC,
and ∼0.02% survival when colistin is used at 50× MIC, which
correspond to approximately 1.7 log and 1.9 log reduction of
viable cells relative to treatment with colistin alone. In
comparison, the combination treatment with KM-5-25 results
in ∼1% survival when colistin is used 25× MIC and ∼0.5%
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in P. aeruginosa as important tools to expose a rare weakness of
bioﬁlms. It is also encouraging that the small molecule
inhibitors of the BfrB-Bfd complex increase the eﬀectiveness
of tobramycin and colistin because the latter is often used as
one of the very few therapeutic options available to combat
multidrug resistant Gram-negative organisms.69,70 The high
level of conservation in the Bfr and Bfd sequences from
P. aeruginosa, A. baumannii, and K. pneumoniae (Figure S7−S8)
suggests that the compounds developed to block the BfrB-Bfd
complex in P. aeruginosa may exert similar activity in
A. baumannii and K. pneumoniae cells.

against P. aeruginosa. In this context, it is noteworthy that the
bfr and bfd genes in A. baumannii and K. pneumoniae strains are
contiguous, as is the case in the >4000 P. aeruginosa genomes
currently available in the Pseudomonas Genome Data Base,
because it suggests that the function of the Bfr-Bfd complex in
P. aeruginosa is conserved in A. baumannii and K. pneumoniae.
Moreover, amino acid sequence alignment with the aid of
Clustal Omega71 reveals very high conservation in the amino
acid sequences of Bfr and Bfd proteins from P. aeruginosa,
A. baumannii and K. pneumoniae (Figure S7−S8). Importantly,
the amino acids identiﬁed as hot spot residues in the BfrB-Bfd
complex of P. aeruginosa33 are highly conserved in the Bfr and
Bfd sequences of A. baumannii and K. pneumoniae, suggesting
that the 4-aminoisoindoline-1,3-dione derivatives designed to
inhibit the BfrB-Bfd interaction in P. aeruginosa are likely to act
similarly in A. baumannii and K. pneumoniae.

■

METHODS
Chemicals, Bacterial Strains, and Growth Media.
Chemicals were purchased from Fisher Scientiﬁc unless
otherwise stated. P. aeruginosa PAO1 was obtained from the
University of Washington Genome center.81 The PAO1 strain
expressing enhanced yellow ﬂuorescent protein (EYFP) was
prepared previously.26 Clinical isolates of P. aeruginosa were
purchased from JMI Laboratories (North Liberty, IA, USA).
IC50 determinations were carried out in deﬁned media (50 mM
KH2PO4 (Sigma-Aldrich) 7.5 mM (NH4)2SO4 (Sigma, Life
Sciences), 0.1% (w/v) glucose (Acros Organics, 99+%), 0.5
mM MgSO4·7H2O (Sigma-Aldrich, 99+%), 5% v/v nonessential amino acids (Gibco), 2% v/v essential amino acids
(Gibco), 4 μM (NH 4 ) 2 Fe(SO 4 ) 2 , and 0.025% (w/v)
hypromellose (HPMC, Sigma-Aldrich), pH 7.0. The media
was ﬁlter-sterilized by passing through a 0.2 μm cellulose
acetate membrane syringe ﬁlter (VWR). Starter cultures of
P. aeruginosa PAO1 in 5 mL LB media were grown for 13 h in
50 mL conical tubes at 37 °C and 220 rpm. For bioﬁlm
experiments, a EYFP-expressing P. aeruginosa strain was
routinely grown in Pseudomonas Isolation (PI) media (20 g
L−1 peptone, 0.3 g L−1 MgCl2·6H2O, 10 g L−1 K2SO4, 25 mg
L−1 irgasan, and 20 mL L−1 glycerol, pH 7.0). Starter cultures
were grown from a single colony at 37 °C and shaking at 220
rpm for 14 h in 5 mL PI media supplemented with 10 μM Fe.
Pellicle bioﬁlms were cultured for 48 h at 30 °C in PI media
supplemented with 20 μM Fe. Surface-attached bioﬁlms were
cultured in AB minimal media82 supplemented with trace
metals [0.15 μM (NH4)2MoO4, 3 μM CuSO4, 2 μM
Co(NO3)2, 9.4 μM Na2B4O7, and 7.6 μM ZnSO4], 3 mM
glucose and 15 μM Fe. Iron supplementation was carried out
by addition of a small volume of ﬁlter-sterilized 10 mM
(NH4)2Fe(SO4)2 (pH ∼ 2.0) solution. The antibiotics
ciproﬂoxacin, colistin and tobramycin were used at concentrations equivalent to 25× and 50× the reported MCI:83
ciproﬂoxacin MIC = 0.25 μg/mL = 0.75 μM; tobramycin MIC
= 0.5 μg/mL = 1.07 μM; colistin MIC = 1 μg/mL = 0.79 μM.
Compound stock solutions (100 mM or 10 mM) in DMSO
(Sigma-Aldrich) were prepared weekly and stored at 4 °C.
Solutions used to treat bioﬁlms or planktonic cells include
0.025% (w/v) HPMC, and 1.5% or 2% DMSO (SigmaAldrich) to prevent aggregation of the analogues in aqueous
solution.
Synthesis and Preparation of 4-Aminoisoindoline1,3-dione Derivatives. Experimental details of the synthetic
protocols developed to prepare the 4-aminoisoindoline-1,3dione derivatives to be tested as inhibitors of the BfrB-Bfd
complex, as well as 1H, 13C NMR and MS data, are presented
in the Supporting Information.
Measurement of Dissociation Constant (Kd). Dissociation constants for the interaction between BfrB and 3-

■

CONCLUDING REMARKS
Bacterial iron metabolism is a vulnerability that may be
exploited in the development of new antimicrobial therapies.
The ﬁeld has centered on four major avenues: (i) The
development of siderophore-antibiotic conjugates aims at
capitalizing on siderophore uptake receptors to enhance
antibiotic cell penetration.72,73 (ii) The sequestration of iron
with the aid of chelators is also directed at depleting
intracellular iron, and whereas iron chelation has been shown
to lead to bioﬁlm dispersion or to prevent bioﬁlm maturation
in vitro,35,37,48,68,74 a potential concern is the probability of
secondary infections fueled by the chelated iron.75,76 (iii) The
perturbation of heme uptake or heme degradation aims at
denying pathogens from using heme, a rich iron source during
infection.77,78 (iv) The perturbation of iron homeostasis with
Ga3+ aims at inducing iron limitation by replacing Fe3+ in the
active site of enzymes with Ga3+ which cannot support the rich
redox chemistry typical of iron.79,80 Systemic Ga3+ treatment
has been shown to improve lung function in patients with
chronic P. aeruginosa infection.56 Our work, which aims at
adding an entirely new strategy for exploiting the bacterial iron
metabolism vulnerability, is directed at inhibiting the
mobilization of iron from bacterioferritin. Blocking iron
mobilization from BfrB by deletion of the bfd gene has been
shown to elicit a breakdown in iron homeostasis due to the
irreversible accumulation of unusable iron in BfrB, which
causes cytosolic iron deﬁciency.23 Because of the relatively high
iron requirement necessary to support the bioﬁlm lifestyle, the
intracellular iron deﬁciency induced in the Δbfd cells has been
shown to result in poorly developed bioﬁlms.26 Encouraged by
these ﬁndings our laboratories have pursued drug discovery
strategies to discover small molecule inhibitors of the BfrB-Bfd
complex, which led us to a series of 4-aminoisoindoline-1,3dione derivatives capable of penetrating the P. aeruginosa cell
envelope, inhibiting the BfrB-Bfd complex and eliciting a cell
growth defect in planktonic cells.25 Additional structural
manipulation of these 4-aminoisoindoline-1,3-dione derivatives
led us to analogues with increased aﬃnity for BfrB and
enhanced bacteriostatic activity against planktonic P. aeruginosa
cells (Table 1). Testing these new derivatives against mature
bioﬁlms revealed that these small molecules inhibit iron
mobilization from BfrB in bioﬁlm-embedded cells (Figure 11)
and kill P. aeruginosa cells in mature bioﬁlms cultured in ﬂow
cells (Figure 6) or in pellicles cultured at the air−liquid
interface (Figure 8). These ﬁndings demonstrate the potential
of small molecules developed to inhibit the BfrB-Bfd complex
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The experimental shear stress was 0.14 dyn/cm2 (shear rate =
14 s−1, pressure = 7.1 mbar, ﬂow rate = 0.4 mL/min) and the
switch time was set to 540 s. The bioﬁlms were treated for 24 h
by ﬂowing AB minimal media supplemented with 15 μM Fe,
0.025% HPMC, 1.5% DMSO and commercial antibiotics or 4aminoisoindoline-1,3-dione derivatives in the concentrations
indicated in the corresponding ﬁgure captions. During bioﬁlm
growth and challenge with antibacterial, the culture medium in
the reservoirs was removed every 12 h and replaced with fresh
prewarmed medium. Prior to imaging with the aid of CLSM
the bioﬁlms were stained with 4 mL of 2.5 nM Sytox Red
(Invitrogen Life Technologies), a cell impermeable ﬂuorescent
nucleic acid dye that stains dead cells and extracellular DNA,85
for 20 min (switch time = 200 s) and then washed with AB
media for 20 min to remove excess ﬂuorescent dye. The
bioﬁlms were imaged with the aid of a Leica TCS SP8 confocal
microscope (Leica Microsystems, Germany) using a HC PL
apo CS2 63 × /1.4 oil objective. For detecting the EYFP
ﬂuorescence the laser line was set at 506 nm and the emission
range to 520−610 nm. Sytox Red ﬂuorescence was detected
with excitation at 631 nm and emission range 637−779 nm.
Image stacks were acquired with a z-step size of 0.3 μm at
randomly chosen positions. The Leica Application Suite X
(LAS-X) software was used for image stack processing.55
Quantitative analysis of bioﬁlm biomass was performed using
the COMSTAT computer program55 and the Otsu method of
automatic thresholding.86
Pellicle Bioﬁlm Assays. Pellicle bioﬁlms of EYFPexpressing P. aeruginosa PAO1 or clinical isolates were grown
in PI media supplemented with 20 μM Fe. Starter cultures
were diluted to OD600 = 0.001 in 4 mL media, placed in 35 ×
10 mm Petri dishes and incubated statically at 30 °C for 48 h.
The pellicles were transferred onto circular (1.5 cm diameter)
glass coverslips by gently allowing the surface of a coverslip to
contact a pellicle. The pellicle-adhered coverslip was washed in
PBS and then deposited on top of 1.5 mL AB challenge media
contained in a well of a 12-well microplate, with the pellicle
exposed to the media. Challenge media consists of AB minimal
media supplemented with 15 μM Fe, 0.025% HPMC, 1.5%
DMSO, and commercial antibiotic or 4-aminoisoindoline-1,3dione derivative, used in the concentrations speciﬁed in the
ﬁgure captions. The 4-aminoisoindoline-1,3-dione derivatives
were prepared as 10 mM stock solutions in DMSO and then
diluted in culture media to the appropriate concentrations. The
coverslip-adhered pellicles were exposed to challenge media at
30 °C for 24 h, changing the challenge media every 12 h by
transferring the pellicle-adhered coverslip to a new plate
containing prewarmed challenge media.
Prior to imaging with the aid of CLSM, pellicles formed by
EYFP-expressing PAO1 cells were washed with PBS and then
stained by placing the coverslip-adhered pellicles in 1 mL of
PBS containing 2.5 nM Sytox Red (20 min). Excess ﬂuorescent
dye was washed with PBS, the coverslip was mounted on a
glass slide using 5 μL SlowFade (Invitrogen Life Technologies)
and the edges sealed with ﬁngernail polish. CLSM image stacks
(z-step size of 0.3 μm) were acquired with the aid of a Leica
TCS SP8 microscope, as described above. Quantitative analysis
was performed by determination of pellicle biomass using
COMSTAT55 and the Otsu method of automatic thresholding.86
Determination of Viable Cells in Pellicle Bioﬁlms.
Pellicle bioﬁlms were grown as described above. Planktonic
and loosely attached cells were washed (3 times) by immersing

aminoisoindoline-1,3-dione derivatives (Table 1, Figure S1)
were measured in vitro with a ﬂuorescence polarization
method based on the intrinsic ﬂuorescence of the isoindoline-1,3-dione moiety, as described previously.25
Measurement of Half Maximal Inhibitory Concentration (IC50). IC50 values (Table 1, Figure S1) were
determined as reported previously25 with small modiﬁcations.
In brief: precultures of P. aeruginosa PAO1 (5 mL) were grown
in LB media for 13 h at 37 °C and 220 rpm in 50 mL conical
tubes (VWR International, PA). The cells were centrifuged for
5 min at 4000 rpm and 4 °C, washed two times and then
diluted in buﬀer (100 mM KH2PO4 and 15 mM (NH4)2SO4)
to an optical density at 600 nm (OD600) of 0.1. A small volume
of compound stock solution (10 mM) was transferred to a
microcentrifuge tube, initially diluted with DMSO to 20 μL,
and then diluted to 1 mL with preculture cell suspension in
deﬁned media with OD600 = 0.0001, so the ﬁnal DMSO
concentration is 2%. The resultant cell suspension (200 μL)
was transferred to a clear-bottom polystyrene 96-well plate
(VWR) covered with a lid and incubated at 35 °C and 205
cpm for 24 h in a Synergy H1 microplate reader (Biotek
Instruments Inc., Vermont). The cell cultures were serially
diluted and then plated on PI Agar (PIA; BD biosciences)
plates for enumeration of viable cells (CFU/mL). The %
growth was calculated from the ratio CFU/mL(treated)/CFU/
mL(untreated control). To calculate the IC50 values, the % growth
was plotted as a function of compound concentration,
expressed as log[compound] (μM), and ﬁtted to the 4parameter logistic model describing the sigmoid-shaped
response pattern (eq 1),84 where b is the slope factor, max is
the upper asymptote (plateau), and min is the lower
asymptote. Values are the average and standard deviation
from three independent experiments.
% growth = min +

max − min
1 + 10(logIC50 − x)b

Article

(1)

Analysis of Secreted Pyoverdine in Planktonic
Cultures. These experiments were conducted in 96 well
plates as described above for the determination of IC50, except
that the cells were cultured in M63 media (2 g/L (NH4)2SO4,
13.6 g/L KH2PO4 (Sigma-Aldrich), 2 g/L glucose, 4 g/L citric
acid, 5 g/L technical grade casamino acids (BD Scientiﬁc),
0.24 g/L MgSO4 (Alfa Aesar), and 0.05% (w/v) HPMC, pH
7.0 adjusted with KOH). Cultures of P. aeruginosa PAO1
treated with KM-5-25 (70 μM) or KM-5-66 (50 μM) were
grown for 27 h prior to diluting the contents of each well in
PBS (pH 7.4) and plating the cells on PIA plates for
enumeration of CFU/mL. The 500-fold diluted solution was
clariﬁed by centrifugation and the pyoverdine in the cell-free
supernatant was analyzed by acquiring ﬂuorescence emission
spectra (430−550 nm) with excitation at 400 nm (10 nm slit
width) and emission at λmax = 460 nm (10 nm slit width) using
a PerkinElmer LS50B spectrophotometer.
Flow Cell Bioﬁlm Assays. Surface-attached bioﬁlms of
P. aeruginosa PAO1 cells expressing EYFP were grown on ﬂow
cells with an 800 μm channel depth (μ-slide I0.8 Luer, Ibidi)
using an automated perfusion system (Ibidi, Munich,
Germany), as described previously.26 Brieﬂy, the ﬂow cell
was inoculated with 200 μL of an overnight culture diluted to
OD600 = 0.5, followed by 1 h incubation at 30 °C to allow
bacterial cell attachment. The μ-slide was connected to the
Ibidi Pump System and the bioﬁlms were cultured for 3 days at
30 °C while ﬂowing AB minimal media containing 15 μM Fe.
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X-ray Crystallography. Crystallization screening of wild
type BfrB was conducted in Compact 300 (Rigaku Reagents)
sitting drop vapor diﬀusion plates at 20 °C using equal
volumes of protein and crystallization solution equilibrated
against 75 μL of the latter. Crystals displaying a prismatic
morphology were obtained in 1−2 days from the Cryo 1−2
HT screen (Rigaku Reagents) condition H6 (30% (v/v) PEG
200, 100 mM Na acetate pH 4.5, 100 mM NaCl). To prepare
the ligand complexes, stock solutions (100 mM) of ligand in
DMSO were mixed with the crystallization solution to obtain a
10 mM ligand soaking solution. Crystals were transferred to
the soaking solution and incubated for 3 h before harvesting
directly from the drop and storing in liquid nitrogen. Due to
the low solubility of KM-5-66, a multicomponent mixture89
composed of 25% (v/v) dioxane, 25% (v/v) glycerol, 25% (v/
v) diethylene glycol and 25% (v/v) ethylene glycol (SM3) was
prepared to improve the ligand solubility. The ligand stock
solution (100 mM in DMSO) was mixed in a 1:1 (v/v) ratio
with SM3; 4 μL of the resultant solution was mixed with 5uL
of 2× crystallant solution and 1 μL of 10× buﬀer (1 M HEPES
pH 7.5) to give a 20 mM ligand solution. Crystals were
transferred to the soaking solution and incubated for 3 h before
harvesting directly from the drop and storing in liquid
nitrogen. Data were collected at the Advanced Photon Source
beamline IMCA-CAT beamline 17-ID. Intensities were
integrated using XDS90 via Autoproc91 and the Laue class
analysis and data scaling were performed with Aimless.92
Structure solution was conducted by molecular replacement
using the previously determined structure of wt holo-BfrB
(PDB: 5D8O)33 as the search model with Phaser.93 Structure
reﬁnement and manual model building were conducted with
Phenix94 and Coot,95 respectively. Structure validation was
conducted with Molprobity.96

the coverslip-adhered pellicles (bioﬁlm facing up) into a well of
a 12-well plate containing 3 mL PBS, and incubating (5 min)
with gentle rocking. To remove the pellicle from the coverslip,
break the extracellular matrix and release cells from the bioﬁlm,
the coverslip-adhered pellicle was placed in a 50 mL conical
tube containing a 2 mL suspension of zirconia beads (0.1 mm
diameter, BioSpec Products), 10 mL PBS, 0.2 μg/mL alginate
lyase and 0.2 μg/mL DNase. The resultant mixture was
incubated at room temperature for 3 min, followed by vigorous
vortexing for 4 min. After sedimentation of the zirconia beads,
a 100 μL aliquot was used for serial dilution and plating on PIA
plates for subsequent enumeration of viable cells (CFU/mL).
Imaging of Iron Stored in BfrB and Analysis of Total
Intracellular Iron in Bioﬁlm-Embedded Cells. Pellicle
bioﬁlms were grown for 48 h as described above. The pellicles
were transferred onto square (2 × 2 cm) glass coverslips by
gently contacting the pellicle with the coverslip. The pellicleadhered coverslip was washed in PBS and then placed in a 50
mL conical tube containing 2 mL suspension of zirconia beads,
15 mL PBS, 0.2 μg/mL alginate lyase and 0.2 μg/mL DNase;
the resultant mixture was incubated (3 min) at room
temperature, and then vortexed vigorously for 4 min. After
the zirconia beads had sedimented, a 100 μL aliquot was
sampled from the cell suspension for plating and enumeration
of viable cells and a 14 mL sample was used to harvest the cells
by centrifugation (20 min, 400 rpm). The cell pellet was
resuspended in 1 mL PBS, transferred to a 1.5 mL
microcentrifuge tube, centrifuged for 10 min at 12 500 rpm
at 4 °C and the cell pellet frozen at −80 °C. The frozen cells
were subjected to three freeze−thaw cycles and then lysed by
addition of 200 μL of lysis buﬀer (50 mM Tris-HCl buﬀer (pH
8.0) containing 10% (v/v) glycerol, 20 mg/mL lysozyme, 0.2
mg/mL DNase, 0.1 M NaCl, 1 mM MgSO4 and 1% (v/v)
Triton-X100) and incubated at ambient temperature (30 min)
and at 37 °C (30 min). Imaging of iron in BfrB was carried out
as previously reported:23 lysate suspensions were clariﬁed by
centrifugation (10 min at 12 500 rpm), mixed with 10 μL
loading dye (5.9 mL deionized water, 0.5 mL glycerol, 0.4 mL
β-mercaptoethanol, 0.4 mL 1% (w/v) bromophenol blue, and
0.5 mL 1 M Tris−HCl (pH 6.8), and loaded onto 1.5 mmthick native PAGE gels (4% stacking gel, 8% resolving gel).
Electrophoresis was carried out at 60 V and 4 °C for 9 h, and
the gels were stained in the dark by immersion (10 min) in a
solution containing 0.049 g Ferene S, 250 μL thioglycolic acid,
2.4 mL acetic acid and 100 mL deionized water. Levels of total
intracellular iron were determined as reported previously:23,87
The cell pellets were treated with 500 μL of freshly prepared
digestion reagent (0.6 N HCl, 2.25% (w/v) KMnO4 in water),
thoroughly mixed by vortexing, and then incubated at 65 °C
for 3.5 h. The resultant solutions were cooled to ambient
temperature, treated with 100 μL of iron detection reagent (6.5
mM Ferene S, 15.4 mM neocuproine, 2 M ascorbic acid, and 5
M ammonium acetate), incubated for 30 min at ambient
temperature and centrifuged for 5 min at 12500 rpm. The iron
concentration was measured from the absorbance of the Fe2+−
Ferene S complex (ε593 = 34.5 mM−1 cm−1),88 normalized by
the viable cell counts and reported as Fe atoms per cell.
Statistical Analysis. Statistical signiﬁcance between the
means and standard deviation of values obtained in experiments comparing results from untreated vs treated with
antibiotic or analogue conditions was determined using oneway ANOVA followed by Tukey’s multiple post hoc test, with
the aid of SigmaPlot (Systat Software, Inc. CA).
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